Roger D Klein, MD, JD, expert with the Regulatory Transparency Project’s FDA and Health Working Group. Former Director of Molecular Oncology at the Cleveland Clinic, former advisor to the FDA, CDC, CMS, and HHS, offers reasons for the delay on coronavirus antibodies with Dan & Amy:
Photo by Marcelo Leal on Unsplash